Sports Medicine

, Volume 42, Issue 2, pp 119–134 | Cite as

Anabolic Steroids and Cardiovascular Risk

  • Peter Angell
  • Neil Chester
  • Danny Green
  • John Somauroo
  • Greg Whyte
  • Keith George
Review Article

Abstract

Recent reports from needle exchange programmes and other public health initiatives have suggested growing use of anabolic steroids (AS) in the UK and other countries. Data indicate that AS use is not confined to bodybuilders or high-level sportsmen. Use has spread to professionals working in emergency services, casual fitness enthusiasts and subelite sportsmen and women. Although the precise health consequences of AS use is largely undefined, AS use represents a growing public health concern. Data regarding the consequences of AS use on cardiovascular health are limited to case studies and a modest number of small cohort studies. Numerous case studies have linked AS use with a variety of cardiovascular disease (CVD) events or endpoints, including myocardial infarction, stroke and death. Large-scale epidemiological studies to support these links are absent. Consequently, the impact of AS use upon known CVD risk factors has been studied in relatively small, case-series studies. Data relating AS use to elevated blood pressure, altered lipid profiles and ECG abnormalities have been reported, but are often limited in scope, and other studies have often produced equivocal outcomes. The use of AS has been linked to the appearance of concentric left ventricular hypertrophy as well as endothelial dysfunction but the data again remains controversial. The mechanisms responsible for the negative effect of AS on cardiovascular health are poorly understood, especially in humans. Possibilities include direct effects on myocytes and endothelial cells, reduced intracellular Ca2+ levels, increased release of apoptogenic factors, as well as increased collagen crosslinks between myocytes. New data relating AS use to cardiovascular health risks are emerging, as novel technologies are developed (especially in non-invasive imaging) that can assess physiological structure and function. Continued efforts to fully document the cardiovascular health consequences of AS use is important to provide a clear, accurate, public health message to the many groups now using AS for performance and image enhancement.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McVeigh J, Beynon C, Bellis MA. New challenges for agency based syringe exchange schemes: analysis of 11 years of data(1991-2001) in Merseyside and Cheshire, United Kingdom. Int J Drug Policy 2003; 14 (5-6): 399–405CrossRefGoogle Scholar
  2. 2.
    Yesalis CE, Bahrke MS. Doping among adolescent athletes. Best Pract Res Clin Endocrinol Metab 2000; 14 (1):25–35CrossRefGoogle Scholar
  3. 3.
    Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. CurrOpin Pharmacol 2004; 4 (6): 614–20PubMedCrossRefGoogle Scholar
  4. 4.
    Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. IntJ Sports Med 1997; 18 (7): 557–62CrossRefGoogle Scholar
  5. 5.
    Ong PJ, Patrizi G, Chong WC, et al. Testosterone enhances flow-mediated brachial artery reactivity in men with coronaryartery disease. Am J Cardiol 2000; 85 (2): 269–72PubMedCrossRefGoogle Scholar
  6. 6.
    Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995;27 (9): 1252–62PubMedGoogle Scholar
  7. 7.
    LeGros T, McConnell D, Murry T, et al. The effects of 17 alpha-methyltestosterone on myocardial function in vitro.Med Sci Sports Exerc 2000; 32 (5): 897–903Google Scholar
  8. 8.
    Belhani D, Fanton L, Vaillant F, et al. Cardiac lesions induced by testosterone: protective effects of dexrazoxaneand trimetazidine. Cardiovasc Toxicol 2009; 9 (2): 64–9PubMedCrossRefGoogle Scholar
  9. 9.
    Morris JN, Heady JA, Raffle PA, et al. Coronary heartdisease and physical activity of work. Lancet 1953; 265 (6796): 1111–20PubMedCrossRefGoogle Scholar
  10. 10.
    Paffenbarger RS, Hale WE. Work activity and coronary heart mortality.N Engl J Med 1975 Mar 13; 292 (11): 545–50PubMedCrossRefGoogle Scholar
  11. 11.
    Pipe A, Hebert PC. Doping, sport and the community. CMAJ 2008; 179 (4): 303–5PubMedGoogle Scholar
  12. 12.
    Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87 (3 Suppl.): II56–65PubMedGoogle Scholar
  13. 13.
    Bots ML, Dijk JM, Oren A, et al. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease:current evidence. J Hypertens 2002; 20 (12): 2317–25PubMedCrossRefGoogle Scholar
  14. 14.
    Sader MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function inmale bodybuilders. J Am Coll Cardiol 2001; 37 (1): 224–30PubMedCrossRefGoogle Scholar
  15. 15.
    Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34 (8): 513–54PubMedCrossRefGoogle Scholar
  16. 16.
    Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. ArchPhys Med Rehabil 1988; 69 (8): 632–3PubMedGoogle Scholar
  17. 17.
    Mochizuki RM, Richter KJ. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenicsteroid use. Phys Sportsmed 1988; 16 (11): 109–11, 114Google Scholar
  18. 18.
    Kennedy MC, Corrigan AB, Pilbeam ST. Myocardial infarction and cerebral haemorrhage in a young body builder taking anabolic steroids. Aust N Z JMed 1993; 23 (6): 713CrossRefGoogle Scholar
  19. 19.
    Akhter J, Hyder S, Ahmed M. Cerebrovascular accident associated with anabolic steroid use in a young man.Neurology 1994; 44 (12): 2405–6PubMedCrossRefGoogle Scholar
  20. 20.
    Sahraian MA, Mottamedi M, Azimi AR, et al. Androgeninduced cerebral venous sinus thrombosis in a young body builder [case report]. BMC Neurol 2004; 4 (1):22PubMedCrossRefGoogle Scholar
  21. 21.
    Santamarina RD, Besocke AG, Romano LM, et al. Ischemic stroke related to anabolic abuse. Clin Neuropharmacol 2008; 31 (2): 80–5PubMedCrossRefGoogle Scholar
  22. 22.
    McNutt RA, Ferenchick GS, Kirlin PC, et al. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 1988; 62 (1): 164PubMedCrossRefGoogle Scholar
  23. 23.
    Bowman S. Anabolic steroids and infarction. BMJ 1990; 300 (6726): 750PubMedCrossRefGoogle Scholar
  24. 24.
    Ferenchick GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J 1992; 124 (2): 507–8PubMedCrossRefGoogle Scholar
  25. 25.
    Kennedy C. Myocardial infarction in association with misuse of anabolic steroids. Ulster Med J 1993; 62 (2): 174–6PubMedGoogle Scholar
  26. 26.
    Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a youngmale body-builder. Int J Cardiol 1994; 44 (2): 171–4PubMedCrossRefGoogle Scholar
  27. 27.
    Huie MJ.An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc 1994; 26 (4): 408–13PubMedGoogle Scholar
  28. 28.
    Fisher M, Appleby M, Rittoo D, et al. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract 1996; 50 (4): 222–3PubMedGoogle Scholar
  29. 29.
    Goldstein DR, Dobbs T, Krull B, et al. Clenbuterol and anabolic steroids: a previously unreported cause of myocardialinfarction with normal coronary arteriograms.South Med J 1998; 91 (8): 780–4PubMedCrossRefGoogle Scholar
  30. 30.
    Fineschi V, Baroldi G, Monciotti F, et al. Anabolic steroid abuse and cardiac sudden death: a pathologic study. ArchPathol Lab Med 2001; 125 (2): 253–5PubMedGoogle Scholar
  31. 31.
    Gunes Y, Erbas C, Okuyan E, et al. Myocardial infarction with intracoronary thrombus induced by anabolic steroids.Anadolu Kardiyol Derg 2004; 4 (4): 357–8PubMedGoogle Scholar
  32. 32.
    Angelilli A, Katz ES, Goldenberg RM. Cardiac arrest following anaesthetic induction in a world-class body builder.Acta Cardiol 2005; 60 (4): 443–4PubMedCrossRefGoogle Scholar
  33. 33.
    Wysoczanski M, Rachko M, Bergmann SR. Acute myocardial infarction in a young man using anabolic steroids.Angiology 2008; 59(3): 376–8PubMedCrossRefGoogle Scholar
  34. 34.
    Lunghetti S, Zaca V, Maffei S, et al. Cardiogenic shock complicating myocardial infarction in a doped athlete.Acute Card Care 2009; 11 (4): 250–1PubMedCrossRefGoogle Scholar
  35. 35.
    Luke JL, Farb A, Virmani R, et al. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings J Forensic Sci 1990; 35 (6): 1441–7PubMedGoogle Scholar
  36. 36.
    Campbell SE, Farb A, Weber KT. Pathologic remodeling of the myocardium in a weightlifter taking anabolic steroids.Blood Press 1993; 2 (3): 213–6PubMedCrossRefGoogle Scholar
  37. 37.
    Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents) and sudden death: a case reportand review of the literature. Int J Legal Med 1998; 111 (5):261–4PubMedCrossRefGoogle Scholar
  38. 38.
    Madea B, Grellner W. Long-term cardiovascular effects of anabolic steroids. Lancet 1998; 352 (9121): 33PubMedCrossRefGoogle Scholar
  39. 39.
    Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of body builders. Int J Legal Med 2007; 121 (1): 48–53PubMedCrossRefGoogle Scholar
  40. 40.
    Laroche GP. Steroid anabolic drugs and arterial complications in an athlete: a case history. Angiology 1990Google Scholar
  41. 41.
    Gaede JT, Montine TJ. Massive pulmonary embolus andanabolic steroid abuse. JAMA 1992; 267 (17):2328–9PubMedGoogle Scholar
  42. 42.
    Jaillard AS, Hommel M, Mallaret M. Venous sinus thrombosis associated with androgens in a healthy youngman. Stroke 1994; 25 (1): 212–3PubMedCrossRefGoogle Scholar
  43. 43.
    Mewis C, Spyridopoulos I, Kuhlkamp V, et al. Manifestation of severe coronary heart disease after anabolic drugabuse. Clin Cardiol 1996; 19 (2): 153–5PubMedCrossRefGoogle Scholar
  44. 44.
    Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17 (10): 1576–83PubMedCrossRefGoogle Scholar
  45. 45.
    Palfi S, Ungurean A, Vecsei L. Basilar artery occlusion associated with anabolic steroid abuse in a 17-year-old body builder. Eur Neurol 1997; 37 (3): 190–1PubMedCrossRefGoogle Scholar
  46. 46.
    Falkenberg M, Karlsson J, Ortenwall P. Peripheral arterial thrombos is in two young men using anabolic steroids. EurJ Vasc Endovasc Surg 1997; 13 (2): 223–6CrossRefGoogle Scholar
  47. 47.
    Hourigan LA, Rainbird AJ, Dooris M. Intracoronary stenting for acute myocardial infarction (AMI) in a 24-year old man using anabolic androgenic steroids. Aust N Z J Med 1998; 28 (6): 838–9PubMedCrossRefGoogle Scholar
  48. 48.
    McCarthy K, Tang AT, Dalrymple-Hay MJ, et al. Ventricular thrombosis and systemic embolism in body builders: etiology and management. Ann Thorac Surg2000; 70 (2): 658–60Google Scholar
  49. 49.
    Ment J, Ludman PF. Coronary thrombus in a 23 year old anabolic steroid user. Heart 2002; 88 (4): 342PubMedCrossRefGoogle Scholar
  50. 50.
    Alhadad A, Acosta S, Sarabi L, et al. Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids Clin Appl Thromb Hemost 2010;16 (2): 228–31CrossRefGoogle Scholar
  51. 51.
    Liljeqvist S, Hellden A, Bergman U, et al. Pulmonary embolism associated with the use of anabolic steroids. EurJ Intern Med 2008; 19 (3): 214–5CrossRefGoogle Scholar
  52. 52.
    Frogel JK, Weiss SJ, Kohl BA. Transesophageal echocardiography diagnosis of coronary sinus thrombosis.Anesth Analg 2009; 108 (2): 441–2PubMedCrossRefGoogle Scholar
  53. 53.
    Mark PB, Watkins S, Dargie HJ. Cardiomyopathy induced by performance enhancing drugs in a competitive body builder.Heart 2005; 91 (7): 888PubMedCrossRefGoogle Scholar
  54. 54.
    Ahlgrim C, Guglin M. Anabolics and cardiomyopathy in a body builder: case report and literature review. J Card Fail 2009; 15 (6): 496–500PubMedCrossRefGoogle Scholar
  55. 55.
    Bispo M, Valente A, Maldonado R, et al.Anabolic steroid induced cardio myopathy underlying acute liver failure ina young body builder. World J Gastroenterol 2009; 15 (23):2920–2PubMedCrossRefGoogle Scholar
  56. 56.
    Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17 (5): 851–7PubMedCrossRefGoogle Scholar
  57. 57.
    Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra,gamma-hydroxybutyrate, and anabolic steroids.Pharmacotherapy 2005; 25 (5): 756–61PubMedCrossRefGoogle Scholar
  58. 58.
    Alaraj AM, Chamoun RB, Dahdaleh NS, et al. Spontaneous subdural haematoma in anabolic steroids dependent weight lifters: reports of two cases and review of literature.Acta Neurochir (Wien) 2005; 147 (1): 85–7; discussion 7-8CrossRefGoogle Scholar
  59. 59.
    Lau DH, Stiles MK, John B, et al. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol 2007; 117 (2): e86–7PubMedCrossRefGoogle Scholar
  60. 60.
    Murai MH, Pecci M, Laursen M. Student Focus left ventricular hypertrophy in a rugby player on anabolicsteroids: a case study. Athl Ther Today 2005; 10 (6): 25–7Google Scholar
  61. 61.
    Ridker PM, Rifai N, Rose L, et al. Comparison of Creactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.N Engl J Med 2002; 347 (20): 1557–65PubMedCrossRefGoogle Scholar
  62. 62.
    Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athelics: crossover double-blind trial on weight lifters.Br Med J 1975; 2(5969): 471–3PubMedCrossRefGoogle Scholar
  63. 63.
    Kuipers H, Wijnen JA, Hartgens F, et al. Influence of anabolic steroids on body composition, blood pressure,lipid profile and liver functions in body builders Int JSports Med 1991; 12 (4): 413–8CrossRefGoogle Scholar
  64. 64.
    Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med SciSports Exerc 1992; 24 (6): 633–7PubMedGoogle Scholar
  65. 65.
    Lane HA, Grace F, Smith JC, et al. Impaired vasore activity in body builders using androgenic anabolic steroids. Eur JClin Invest 2006; 36 (7): 483–8CrossRefGoogle Scholar
  66. 66.
    Baldo-Enzi G, Giada F, Zuliani G, et al. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism1990; 39 (2): 203–8PubMedCrossRefGoogle Scholar
  67. 67.
    Zmuda JM, Fahrenbach MC, Younkin BT, et al. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism1993; 42 (4):446–50PubMedCrossRefGoogle Scholar
  68. 68.
    Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic- anabolic steroids on a polipoproteins and lipoprotein(a). Br J Sports Med 2004; 38 (3): 253–9PubMedCrossRefGoogle Scholar
  69. 69.
    Grace FM, Davies B. Raised concentrations of C reactive protein in anabolic steroid using body builders. Br J Sports Med 2004; 38 (1): 97–8PubMedCrossRefGoogle Scholar
  70. 70.
    Zmuda JM, Bausserman LL, Maceroni D, et al. The effect of supraphysiologic doses of testosterone on fasting total homocysteine levels in normal men Atherosclerosis 1997;130 (1-2): 199–202PubMedCrossRefGoogle Scholar
  71. 71.
    Graham MR, Grace FM, Boobier W, et al. Homocysteine induced cardiovascular events: a consequence of long termanabolic-androgenic steroid (AAS) abuse. Br J Sports Med 2006; 40 (7): 644–8PubMedCrossRefGoogle Scholar
  72. 72.
    Alén M. Androgenic steroid effects on liver and red cells Br J Sports Med 1985; 19 (1): 15–20PubMedCrossRefGoogle Scholar
  73. 73.
    Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health 1957; 47 (4 Pt 2): 4–24PubMedCrossRefGoogle Scholar
  74. 74.
    Chaney RH, Eyman RK. Blood pressure at rest and during maximal dynamic and isometric exercise as predictorsof systemic hypertension. Am J Cardiol 1988; 62 (16):1058–61PubMedCrossRefGoogle Scholar
  75. 75.
    Kawano H, Tanimoto M, Yamamoto K, et al. Resistance training in men is associated with increased arterial stiffness and blood pressure but does not adversely affect endothelial function as measured by arterial reactivity to thecold pressor test. Exp Physiol 2008; 93 (2): 296–302PubMedCrossRefGoogle Scholar
  76. 76.
    Kasikcioglu E, Oflaz H, Arslan A, et al. Aortic elastic properties in athletes using anabolic-androgenic steroids.Int J Cardiol 2007; 114 (1): 132–4PubMedCrossRefGoogle Scholar
  77. 77.
    Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J AmColl Cardiol 2009; 53 (4): 316–22PubMedCrossRefGoogle Scholar
  78. 78.
    Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increasein hepatic triglyceride lipase precedes the decrease in highdensity lipoprotein 2 cholesterol. Metabolism 1987; 36 (10):949–52PubMedCrossRefGoogle Scholar
  79. 79.
    Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factorfor vascular disease: probable benefits of increasing folicacid intakes. JAMA 1995; 274 (13): 1049–57PubMedCrossRefGoogle Scholar
  80. 80.
    McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 2005; 43 (10):980–6Google Scholar
  81. 81.
    Hartgens F, Hamulyak K, Pernot C, editors. Effects of high doses androgenic-anabolic steroids on haematologic parameters in body builders [abstract]. 8th FIMS European Sports Medicine Congress 1995: 23–7Google Scholar
  82. 82.
    Savage DD, Levy D, Dannenberg AL, et al. Association of echocardiographic left ventricular mass with body size,blood pressure and physical activity (the FraminghamStudy). Am J Cardiol 1990; 65 (5): 371–6PubMedCrossRefGoogle Scholar
  83. 83.
    Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115 (18): 2390–7PubMedCrossRefGoogle Scholar
  84. 84.
    Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization:possible role of testosterone. Am Heart J 2000;140 (4): 678–83PubMedCrossRefGoogle Scholar
  85. 85.
    Fulop L, Banyasz T, Szabo G, et al. Effects of sex hormones on ECG parameters and expression of cardiac ion channelsin dogs. Acta Physiol (Oxf) 2006; 188 (3-4): 163–71CrossRefGoogle Scholar
  86. 86.
    Stolt A, Karila T, Viitasalo M, et al. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol 1999;84 (3): 364–6, A9PubMedCrossRefGoogle Scholar
  87. 87.
    Bigi MA, Aslani A. Short QT interval: a novel predictor of androgen abuse in strength trained athletes. Ann Non invasive Electrocardiol 2009; 14 (1): 35–9CrossRefGoogle Scholar
  88. 88.
    Liu XK, Katchman A, Whitfield BH, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc Res 2003; 57 (1): 28–36PubMedCrossRefGoogle Scholar
  89. 89.
    Urhausen A, Holpes R, Kindermann W. One- and two dimensional echo cardiography in body builders using anabolic steroids. Eur J Appl Physiol Occup Physiol 1989;58 (6): 633–40PubMedCrossRefGoogle Scholar
  90. 90.
    Sachtleben TR, Berg KE, Elias BA, et al. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 1993; 25 (11): 1240–5PubMedGoogle Scholar
  91. 91.
    Dickerman RD, Schaller F, McConathy WJ. Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid use. Cardiology 1998; 90(2): 145–8PubMedCrossRefGoogle Scholar
  92. 92.
    Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes.Int J Sports Med 2003; 24 (5): 344–51PubMedCrossRefGoogle Scholar
  93. 93.
    Nottin S, Nguyen LD, Terbah M, et al. Cardiovascular effects of androgenic anabolic steroids in male body builders determined by tissue Doppler imaging. AmJ Cardiol 2006; 97 (6): 912–5CrossRefGoogle Scholar
  94. 94.
    D’Andrea A, Caso P, Salerno G, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med 2007; 41 (3): 149–55PubMedCrossRefGoogle Scholar
  95. 95.
    Kasikcioglu E, Oflaz H, Umman B, et al. Androgenic anabolic steroids also impair right ventricular function. Int J Cardiol 2009; 134 (1): 123–5PubMedCrossRefGoogle Scholar
  96. 96.
    Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail 2010; 3 (4): 472–6PubMedCrossRefGoogle Scholar
  97. 97.
    Krieg A, Scharhag J, Albers T, et al. Cardiac tissue Doppler in steroid users. Int J Sports Med 2007; 28 (8): 638–43PubMedCrossRefGoogle Scholar
  98. 98.
    Langeland S, D’Hooge J, Wouters PF, et al. Experimental validation of a new ultrasound method for the simultaneous assessment of radial and longitudinal myocardial deformation independent of insonation angle. Circulation 2005; 112 (14): 2157–62PubMedCrossRefGoogle Scholar
  99. 99.
    Marsh JD, Lehmann MH, Ritchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 1998; 98 (3): 256–61PubMedCrossRefGoogle Scholar
  100. 100.
    Krieg A, Scharhag J, Kindermann W, et al. Cardiac tissue Doppler imaging in sports medicine. Sports Med 2007;37 (1): 15–30PubMedCrossRefGoogle Scholar
  101. 101.
    Lieberherr M, Grosse B. Androgens increase intracellular calcium concentration and inositol 1, 4, 5-trisphosphateand diacylglycerol formation via a pertussis toxin sensitive G-protein. J Biol Chem 1994; 269 (10): 7217–223PubMedGoogle Scholar
  102. 102.
    Zaugg M, Jamali NZ, Lucchinetti E, et al. Anabolic androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol 2001; 187 (1): 90–5PubMedCrossRefGoogle Scholar
  103. 103.
    Takase B, Uehata A, Akima T, et al. Endotheliumdependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. AmJ Cardiol 1998; 82 (12): 1535–9, A7-8CrossRefGoogle Scholar
  104. 104.
    Takase B, Hamabe A, Satomura K, et al. Close relationship between the vasodilator response to acetylcholine in the brachial and coronary artery in suspected coronaryartery disease. Int J Cardiol 2005; 105 (1): 58–66PubMedCrossRefGoogle Scholar
  105. 105.
    Green DJ, Cable NT, Rankin JM, et al. Anabolic steroids and vascular responses. Lancet 1993; 342 (8875): 863PubMedCrossRefGoogle Scholar
  106. 106.
    Gokce N, Keaney Jr JF, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41 (10):1769–75PubMedCrossRefGoogle Scholar
  107. 107.
    Ebenbichler CF, Sturm W, Ganzer H, et al. Flowmediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 2001; 158 (2): 483–90PubMedCrossRefGoogle Scholar
  108. 108.
    Miyachi M, Kawano H, Sugawara J, et al. Unfavorable effects of resistance training on central arterial compliance a randomized intervention study. Circulation 2004; 110 (18): 2858–63PubMedCrossRefGoogle Scholar
  109. 109.
    Rakobowchuk M, McGowan CL, de Groot PC, et al. Endothelial function of young healthy males following whole body resistance training. J Appl Physiol 2005; 98 (6):2185–90PubMedCrossRefGoogle Scholar
  110. 110.
    McCredie RJ, McCrohon JA, Turner L, et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 1998; 32 (5): 1331–5CrossRefGoogle Scholar
  111. 111.
    D’Ascenzo S, Millimaggi D, Di Massimo C, et al. Detrimental effects of anabolic steroids on human endothelialcells. Toxicol Lett 2007; 169 (2): 129–36PubMedCrossRefGoogle Scholar
  112. 112.
    Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits.Pharmacol Res 2004; 50 (3): 253–9PubMedCrossRefGoogle Scholar
  113. 113.
    McCrohon JA, Jessup W, Handelsman DJ, et al. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascularcell adhesion molecule-1. Circulation 1999; 99 (17):2317–22CrossRefGoogle Scholar
  114. 114.
    Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol Methods 1995; 33 (4): 187–95PubMedCrossRefGoogle Scholar
  115. 115.
    Welder AA, Robertson JW, Fugate RD, et al. Anabolicandrogenic steroid-induced toxicity in primary neo natal rat myocardial cell cultures. Toxicol Appl Pharmacol1995; 133 (2): 328–42PubMedCrossRefGoogle Scholar
  116. 116.
    O’Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolicandrogenic steroids: medical assessment of present, past and potential users. Med J Aust 2000; 173 (6): 323–7PubMedGoogle Scholar
  117. 117.
    Thevis M, Schrader Y, Thomas A, et al. Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches. J Anal Toxicol 2008; 32 (3): 232–40PubMedGoogle Scholar
  118. 118.
    Evans-Brown M, Dawson R, McVeigh J. The dire consequences of doping [letter] Lancet 2008; 372 (9649): 1544PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Peter Angell
    • 1
  • Neil Chester
    • 1
  • Danny Green
    • 1
    • 2
  • John Somauroo
    • 3
  • Greg Whyte
    • 1
  • Keith George
    • 1
  1. 1.Research Institute for Sport and Exercise SciencesLiverpool John Moores University, Tom Reilly BuildingLiverpoolUK
  2. 2.School of Sport Science, Exercise and HealthThe University of Western AustraliaNedlandsAustralia
  3. 3.Cardiology DepartmentCountess of Chester Hospital NHS Foundation Trust, Countess of Chester Health ParkChester, CheshireUK

Personalised recommendations